EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection

Svenja Hardtke, Cihan Yurdaydin iD, Florin A Caruntu, Manuela G Curescu, Kendal Yalcin, Ulus S Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V Papatheodoridis iD, Kerstin Port und 4 weitere

Journal of Viral Hepatitis · 2025

DOI: 10.1111/jvh.70022 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Svenja Hardtke und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Interferon-alpha, Polyethylene Glycols, Antiviral Agents, Hepatitis D. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HepNet Study-House (a project of the German Liver Foundation founded by the German Liver Foundation, the German Ministry for Education and Research, and the Ge…, F. Hoffmann-La Roche, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon‐alfa‐2a (PEG‐IFNa) for the treatment of hepatitis D. In the HIDIT‐II study, 120 patients were treated for 96 weeks with PEG‐IFNa (180 μg weekly) in combination with tenofovir disoproxil fumarate (TDF, 300 mg once daily) or placebo. Hepatitis flares were defined as ALT increases above 10 times the upper limit of normal or increases of more than 2.5‐fold above baseline or nadir values. ALT flares occurred in 28 patients (23%) during treatment (< 96) and in 14 patients post‐treatment until follow‐up Week 24. There were no differences in the flare frequency between the two treatment arms (12 PEG‐IFNa + placebo vs. 16 PEG‐IFNa + TDF). The frequency of ALT increases did not differ between cirrhotic and noncirrhotic patients. None of the patients with cirrhosis experienced liver decompensation during or after a flare. Fifty‐four per cent of the patients with ALT flare experienced a decrease in HDV RNA (> 1 log10 cop/ml) during subsequent study visits. Mean ALT levels early during treatment were higher in patients with HBsAg loss at follow‐up Week 24. More than a third of hepatitis D patients undergoing PEG‐IFNa therapy may experience ALT flares during or after treatment. ALT flares in this study posed no obvious safety risk to patients and should not lead to premature withdrawal from treatment. If ALT flares may be beneficial in single patients requires further investigation. Clinical Trial Registration: NCT00932971, EudraCT 2008–005560‐13.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-alphaPolyethylene GlycolsAntiviral AgentsHepatitis DHepatitis D, ChronicHumansMaleFemaleRecombinant ProteinsAdultMiddle AgedAlanine TransaminaseTenofovirRNA, ViralViral LoadPlacebosTreatment OutcomeSeverity of Illness IndexDrug Therapy, CombinationAged

Stichwörter der Autor:innen

HDVHIDIT‐IIalanine aminotransferasebeneficial flarescombination therapydeltahepatitis flaresinterferonrandomised trialvirological outcome

Substanzen

Interferon-alphaPolyethylene GlycolsAntiviral Agentspeginterferon alfa-2aRecombinant ProteinsAlanine TransaminaseTenofovirRNA, ViralPlacebos

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany.
  • German Center for Infectious Disease Research (DZIF), HepNet Study-House/German Liver Foundation, Hannover, Germany.
  • University Hospital Hamburg Eppendorf, Institute for Infection Research and Vaccine Development, Hamburg, Germany.
  • Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.
  • Department of Gastroenterology & Hepatology, Koc University Medical School, Istanbul, Turkey.
  • Institutul de Boli Infectioase, Bucharest, Romania.

ORCID-Profile: Cihan Yurdaydin, George V Papatheodoridis, Markus Cornberg, Heiner Wedemeyer

Förderung

  • HepNet Study-House (a project of the German Liver Foundation founded by the German Liver Foundation, the German Ministry for Education and Research, and the Ge…
  • F. Hoffmann-La Roche
  • Gilead Sciences

Zitieren

APA

Hardtke, S., Yurdaydin, C., Caruntu, F. A., Curescu, M. G., Yalcin, K., Akarca, U. S., Gürel, S., Zeuzem, S., Erhardt, A., Lüth, S., Papatheodoridis, G. V., Port, K., Manns, M. P., Cornberg, M., Kahlhöfer, J., & Wedemeyer, H. (2025). Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70022

Vancouver

Hardtke S, Yurdaydin C, Caruntu FA, Curescu MG, Yalcin K, Akarca US, et al. Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70022

BibTeX
@article{Hardtke2025,
  author = {Hardtke, Svenja and Yurdaydin, Cihan and Caruntu, Florin A and Curescu, Manuela G and Yalcin, Kendal and Akarca, Ulus S and Gürel, Selim and Zeuzem, Stefan and Erhardt, Andreas and Lüth, Stefan and Papatheodoridis, George V and Port, Kerstin and Manns, Michael P and Cornberg, Markus and Kahlhöfer, Julia and Wedemeyer, Heiner},
  title = {Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection},
  journal = {Journal of Viral Hepatitis},
  year = {2025},
  doi = {10.1111/jvh.70022}
}
Kostenlos starten →